Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 126 Tessália Vieira de Camargo St, Campinas, Sao Paulo, 13083-887, Brazil.
Department of Surgery, Faculty of Medicine of Jundiaí, Jundiaí, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3227-3238. doi: 10.1007/s00210-023-02805-x. Epub 2023 Nov 1.
6-Nitrodopamine (6-ND) is released from human vas deferens and plays a modulatory role in the male ejaculation. Therapeutical use of α-adrenoceptor antagonists is associated with ejaculatory abnormalities. To evaluate the effect of α-adrenoceptor antagonists on the contractions induced by 6-ND, dopamine, noradrenaline, and adrenaline in the human epididymal vas deferens (HEVD). HEVD strips were suspended in glass chambers containing heated and oxygenated Krebs-Henseleit's solution. Cumulative concentration-response curves to catecholamines (10 nM-300 μM) were constructed in HEVD strips pre-incubated (30 min) with doxazosin (0.1-1 nM), tamsulosin (1-10 nM), prazosin (10-100 nM) and/or silodosin (0.1-10 nM). The effects of these α-adrenoceptor antagonists were also evaluated in the electric-field stimulation (EFS, 2-32 Hz)-induced contractions. Doxazosin (0.1 nM) caused significant reductions in 6-ND-induced HEVD contractions without affecting the contractions induced by dopamine, noradrenaline, and adrenaline. Similar results were observed with tamsulosin (1 nM) and prazosin (10 nM). At these concentrations, these α-adrenoceptor antagonists largely reduced the EFS-induced contractions. Silodosin (1 nM) caused concentration-dependent rightward shifts of the concentration-response curves to 6-ND but had no effect on the contractions induced by dopamine and adrenaline. Silodosin (0.1 nM) only inhibited the contractions induced by noradrenaline. Silodosin at 1 nM, but not at 0.1 nM, caused significant reductions in the EFS-induced contractions. The results reinforce the concept that 6-ND plays a major role in the human vas deferens contractility and indicate that the ejaculation disorders caused by doxazosin, tamsulosin, prazosin and silodosin cause in man, may be due to inhibition of the contractions induced by 6-ND rather than by the classical catecholamines dopamine, noradrenaline, and adrenaline.
6-硝基多巴胺(6-ND)从人输精管中释放出来,并在男性射精中发挥调节作用。α-肾上腺素受体拮抗剂的治疗用途与射精异常有关。评估 α-肾上腺素受体拮抗剂对 6-ND、多巴胺、去甲肾上腺素和肾上腺素诱导的人附睾输精管(HEVD)收缩的影响。HEVD 条带悬挂在含有加热和充氧的 Krebs-Henseleit 溶液的玻璃室中。在预先孵育(30 分钟) doxazosin(0.1-1 nM)、tamsulosin(1-10 nM)、prazosin(10-100 nM)和/或 silodosin(0.1-10 nM)的 HEVD 条带中构建对儿茶酚胺(10 nM-300 μM)的累积浓度反应曲线。还评估了这些 α-肾上腺素受体拮抗剂在电刺激(EFS,2-32 Hz)诱导收缩中的作用。 doxazosin(0.1 nM)导致 6-ND 诱导的 HEVD 收缩显著减少,而不影响多巴胺、去甲肾上腺素和肾上腺素诱导的收缩。tamsulosin(1 nM)和 prazosin(10 nM)也观察到类似的结果。在这些浓度下,这些 α-肾上腺素受体拮抗剂大大减少了 EFS 诱导的收缩。silodosin(1 nM)导致 6-ND 浓度反应曲线的浓度依赖性右移,但对多巴胺和肾上腺素诱导的收缩没有影响。silodosin(0.1 nM)仅抑制去甲肾上腺素诱导的收缩。silodosin(1 nM)而非 0.1 nM 导致 EFS 诱导的收缩显著减少。结果强化了 6-ND 在人输精管收缩性中起主要作用的概念,并表明 doxazosin、tamsulosin、prazosin 和 silodosin 引起的射精障碍在男性中可能是由于抑制 6-ND 诱导的收缩而不是经典儿茶酚胺多巴胺、去甲肾上腺素和肾上腺素引起的。